News & Updates

The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.

A hepatitis C virus (HCV) micro-elimination programme targeting high-risk groups can enhance the effectiveness of screening and significantly shorten the time to starting direct-acting antiviral (DAA) therapy without compromising treatment outcomes, researchers at the University of Hong Kong (HKU) have reported.

Higher intake of alcohol and reduced care during the COVID-19 pandemic have triggered a spike in alcohol-related liver diseases, leading to some serious consequences, according to new research.

Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.